From Barchart:

The article focuses on two pharmaceutical companies with a presence in the anti-obesity market. Wall Street analysts provide insights on their performance and future potential. The analysis includes an upside forecast for the stocks leading into 2024. This provides investors and stakeholders with valuable information about the pharmaceutical industry and potential investment opportunities. The article also highlights the growing importance of the anti-obesity market within the healthcare sector. Overall, it offers a comprehensive overview of the pharmaceutical landscape and the potential for growth in the coming years.



Read more: 2 Mega-Cap Pharma Stocks to Buy for More Upside